16-12-2011 11:02 Decemer 2, 2011 - Genomics in Medicine Lecture Series More: http://www.genome.gov Excerpt from: The Human Genome and Individualized Medicine - David Valle, MD - Video … Continue reading →

MONTREAL--(BUSINESS WIRE)-- Thrasos today announced that the journal Nature Medicine has published the results of a collaborative research program detailing the role of the bone morphogenic protein (BMP) pathway in the development of kidney disease. This research was led by Dr. Raghu Kalluri, Professor of Medicine at Harvard Medical School, Beth Israel Deaconess Medical Center, in collaboration with the Thrasos research team and Dr. Mary Rusckowski, Associate Professor at the University of Massachusetts Medical School. Dr. Kalluri is a world-recognized expert in understanding of the process of renal fibrosis and the role of BMPs in controlling that process. The research describes the potential for Thrasos’ compounds to specifically target receptors in this pathway, potentially leading to the control of fibrosis and induction of kidney regeneration. BMPs are key regulators of inflammation, fibrosis and apoptosis. High-affinity receptors for specific BMPs are present in kidney epithelial cells and are thought to mediate BMP actions in the kidney. One such receptor is activin-like kinase 3 (Alk3). The comprehensive set of preclinical studies detailed in the Nature Medicine article demonstrate that Alk3 is elevated early in diseased kidneys following injury and also suggest that Alk3-mediated signaling can protect kidneys by inhibiting fibrosis. This research … Continue reading →

NEW YORK--(BUSINESS WIRE)-- IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK) (PINKSHEETS: SVFC.PK); (“IntelliCell”) or the (“Company”), was invited to demonstrate its stromal vascular fraction technology at the recent Baseball Injuries Symposium at the Andrews Sports Medicine Institute in Alabama held and sponsored by USA Baseball. The course Chairman is Dr. James Andrews, and moderated by PT Kevin Wilk, and Dr. Jeff Dugas. One of the courses presented during the three day event was on stem cell technology presented by Dr. Joshua Hackel. Dr. Hackel presented the state of regenerative medicine technology in the role of treating sports injuries. The link is http://www.mediafire.com/?u7bfa662e3r1sdp. Dr. Hackel compared the IntelliCell SVF technology to several other methods of regenerative medicine being considered to be used by the leading orthopedic sports medicine doctors. Dr. Steven Victor, CEO of IntelliCell stated, "We are extremely excited that IntelliCell’s technology compares very favorably to all the other technologies, for procedures common to all major sports industries. We are extremely grateful to have the opportunity to present to over 200 leading doctors and trainers looking to treat major league, collegiate and amateur baseball players with regenerative medicine. IntelliCell Biosciences believes that its technology will be utilized by such experts this year." … Continue reading →

RED BANK, NJ--(Marketwire -02/07/12)- American CryoStem Corporation (OTCQB: CRYO.OB - News) announced today that it has completed providing stem cell processing services for Personal Cell Sciences Corp., a cutting edge manufacturer of anti-aging skin care products. The study involves researching the regenerative function of a conditioned medium obtained from each participant's adipose (fat tissue) derived mesenchymal stem cells and their ability to promote the production or secretion of collagen, elastin and fibronectin related to skin wound healing. John Arnone, CEO of American CryoStem and Founder of Personal Cell Sciences, commented, "CRYO's patented tissue culture media and its proprietary, aseptic adipose tissue processing methodology allows, as an added benefit for PCS customers to store a clinical grade sample of their own stem cells for future use in regenerative medicine. We are pleased to provide comprehensive Bio-Insurance storage solutions at our clinical facility." The adipose tissue samples were acquired utilizing a mini-liposuction procedure. A total of sixty milliliters (approximately 2 fluid ounces) of adipose tissue was collected in the physician's office and sent to CRYO's laboratory for processing. Once processed, the resulting stromal vascular fraction (SVF) was forwarded to the Personal Cell Sciences laboratory for proprietary formulation for patient specific products. "We … Continue reading →